@article{3afadb88340345eb88ae11db99ddb0e4,
title = "Summary of the proceedings of the Basic Science of Uterine Fibroids meeting: new developments (February 28, 2020)",
abstract = "Scientists from multiple basic disciplines and an international group of physician-scientists from the fields of obstetrics and gynecology presented recent studies and discussed new and evolving theories of uterine fibroid etiology, growth, and development at the Basic Science of Uterine Fibroids meeting, sponsored by the Campion Fund and the National Institute of Environmental Health Sciences. The purpose was to share up-to-date knowledge and stimulate new concepts regarding the basic molecular biology and pathophysiology of uterine fibroids and promote future collaborations. The meeting was held at the National Institutes of Environmental Health Sciences in North Carolina on February 28, 2020. The speakers reviewed recent advances in cellular and molecular processes that contribute to fibroid growth and new opportunities for treatment. At the conclusion of the conference, attendees identified important new directions for future research.",
keywords = "etiology, fibroids, pathobiology",
author = "Leppert, {Phyllis C.} and Ayman Al-Hendy and Baird, {Donna D.} and Serdar Bulun and William Catherino and Darlene Dixon and Merrick Ducharme and Harmon, {Quaker E.} and Jayes, {Friederike L.} and Emmanuel Paul and Perucho, {Aymara Mas} and James Segars and Carlos Sim{\'o}n and Stewart, {Elizabeth A.} and Jose Teixeira and Andrea Tinelli and Daniel Tschumperlin and Zota, {Ami R.}",
note = "Funding Information: Supported in part by the Intramural Research Program of the National Institutes of Health , NIEHS . Funding Information: Conflicts of Interest: C.S. reports personal fees from IGENOMIX, FERRING, MERCKSERONO, MSD, TEVA, and THERAMEX, outside the submitted work. P.C.L. reports grants from Advanced BioFactures, during the conduct of the study. In addition, P.C.L. has a patent Leppert, Wegman, Biospecifics Technologies Corp, Method of Treatment of Uterine Fibroids with collagenase issued. F.L.J. reports grants from BioSpecifics Technologies Corporation, during the conduct of the study; grants and nonfinancial support from BioSpecifics Technologies Corporation, outside the submitted work. J.S. reports grants from Biospecifics Inc, during the conduct of the study. W.C. reports consultancy for AbbVie, Bayer, Myovant, Allergan, and ObsEva; grants from Uniformed Services University of the Health Sciences, National Institute of Child Health and Human Development, and Gynecologic Oncology Center of Excellence, outside the submitted work. E.A.S. reports personal fees from Bayer, AbbVie, Myovant, UpToDate, Med Learning Group, PeerView, and ObsEva, outside the submitted work; in addition, E.A.S. has a patent Methods and Compounds for Treatment of Abnormal Uterine Bleeding 6440445 issued. https://www.fertstertdialog.com/posts/xfss-d-20-00042 . All other authors have nothing to disclose. Funding Information: Supported in part by the Campion Fund of the Phyllis and Mark Leppert Foundation for Fertility Research . Funding Information: Research on injectable collagenase treatment funded by Advance Biofactures Corporation, Lynbrook, New York. Publisher Copyright: {\textcopyright} 2020 American Society for Reproductive Medicine",
year = "2021",
month = feb,
doi = "10.1016/j.xfss.2020.11.001",
language = "English (US)",
volume = "2",
pages = "88--100",
journal = "F and S Science",
issn = "2666-335X",
number = "1",
}